Date: 2012-11-12
Type of information: R&D agreement
Compound: identification of genomic alterations found in cancer-related tumor genes that may predict a person’s response or resistance to targeted medicines.
Company: AstraZeneca (UK) Foundation Medicine (USA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: Foundation Medicine has announced a multi-year collaboration with AstraZeneca to identify alterations found in cancer-related tumor genes that may predict a person’s response or resistance to targeted medicines. Working with Foundation Medicine to reveal these genomic alterations may help AstraZeneca to research new medicines for people with cancer. Under the terms of the collaboration, Foundation Medicine was also granted right of first negotiation for the development of potential diagnostic products.
Financial terms:
Latest news:
